CARY, NC - Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease, was selected by SpringWorks Therapeutics as a limited distribution specialty pharmacy for OGSIVEO™ (nirogacestat), which is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment.
OGSIVEO, which was approved on Nov. 27, 2023, by the U.S. Food and Drug Administration (FDA) based on response data from the DeFi trial, is an oral, selective, small molecule gamma secretase inhibitor for the treatment of adult patients with progressing desmoid tumors. OGSIVEO is the first drug to be approved for this rare type of non-cancerous tumor. Also referred to as aggressive fibromatosis, desmoid tumors are locally invasive, slow growing soft tissue tumors. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and occasionally mortality in patients.
“OGSIVEO provides a new therapy option for patients impacted by desmoid tumors, which is a unique, rare, and sometimes unpredictable disease,” said Ela Lourido, vice president and general manager, Specialty Pharmacy Solutions, McKesson. “Biologics is honored to be chosen as a specialty pharmacy provider by SpringWorks to offer this important medication to patients who need it.”
Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
For more information about the symptoms, diagnosis, and treatment of desmoid tumors, please click here. For more information about OGSIVEO, including full prescribing information, please click here.
OGSIVEO™ is a trademark of SpringWorks Therapeutics Inc.
